Mithrl has announced a $20 million Series A, led by Obvious Ventures, with participation from Headline, AGI House, and several pharmaceutical executives. The announcement brings up an increasingly important challenge in...read more
Features and insights
A Single-Cell Map of the Human Immune System Across Lifespan
The status of the human immune system is heavily involved in both disease defense and healthy aging or its converse. At enligtenbio we have an interest in understanding human immune function and how immune changes link...read more
How AI Language Models Are Uncovering Hidden Bacterial Immune Systems
How artificial intelligence is revealing thousands of previously unknown bacterial antiviral defense systems, and why they could become the next generation of biotechnology tools TL;DR: Two recently published science...read more
The Dangerous Bet Behind Big Pharma’s Silence
Why dismantling America’s biomedical innovation engine is a long-term threat to the very industry staying quiet about it. A recent piece by Steven Usdain, which was also highlighted by Holden Thorp, got me thinking: are...read more
When “Anonymous” Isn’t: The UK Biobank Data Exposure and the Limits of Health Data Privacy
The UK Biobank data exposure highlights a growing risk in modern health research: sensitive data is not only vulnerable to breaches, but to systemic leakage through normal scientific practices. This raises urgent...read more
From Surveys to Signals: How AI Is Changing Voice of the Customer in Life Sciences
From Surveys to Signals: How AI Is Changing Voice of the Customer in Life Sciences I’ve been spending some time thinking on how Voice of the Customer (VoC) programs are evolving as artificial intelligence (AI) becomes...read more
Tempus Scoops Up OneOme’s Pharmacogenetics Assets as Precision Medicine Shakeout Continues
Tempus AI has acquired the pharmacogenetics assets of OneOme, a once-promising precision medicine startup that abruptly shut down earlier this year amid financial troubles. The deal marks the latest in a flurry of...read more
New Therapy Potential of Targeted Protein Degradation
New approaches in drug discovery currently focus on the concept of a „magic bullet“ molecule. One that precisely targets an intended pharmacological role without off-target actions or unwanted side-effects. Traditional...read more
Stop Guessing. Start Diagnosing: The Marketing & Product-Market Fit Scorecard
I recently conducted a LinkedIn survey to understand why most startups fail. I asked “Most startups don’t fail because of a bad idea — they fail because founders ignore the warning signs. I’m curious — which of these do...read more
Why Are We Still Talking About Data Infrastructure for Life Sciences in 2025?
“In my twenty-five years in the Life Sciences industry, I’ve observed countless organizations adopt, revise, dismantle, and rebuild their data infrastructure.” While the rapid advancements of data technology certainly...read more
